Physician profile
Ellen E Mclimore
NPI 1376853473
$5,821.20
in general payments reported to CMS, 2019-2025
22 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $684 · 2022: $1,380 · 2023: $1,310 · 2024: $1,317 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,658 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,658.16 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,024.59 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $640.15 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $603.98 | 2021-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $600.49 | 2021-2025 | Eliquis, Camzyos |
| Amgen INC. | $585.63 | 2021-2025 | Repatha, Repatha |
| Pfizer INC. | $572.65 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $382.91 | 2022-2025 | Farxiga, Andexxa, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $366.06 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $201.85 | 2022-2025 | Verquvo, Capvaxive |
| Esperion Therapeutics, INC. | $176.15 | 2021-2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $129.05 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $126.80 | 2022-2023 | |
| Abiomed | $99.63 | 2025 | |
| Alnylam Pharmaceuticals INC. | $72.51 | 2024-2025 | Onpattro, Amvuttra |
| Boston Scientific Corporation | $59.00 | 2022-2025 | Bodyguardian, Cds - Mct/Cem Monitoring |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $45.83 | 2024-2025 | |
| Amarin Pharma, INC. | $37.08 | 2021 | |
| Scpharmaceuticals INC. | $24.16 | 2025 | |
| Abbott Laboratories | $23.81 | 2024 | Jot Dx |
| Kiniksa Pharmaceuticals, Ltd. | $17.27 | 2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $17.12 | 2023 | Opsumit, Uptravi |
| Inspire Medical Systems, INC. | $14.48 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Mclimore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.